Publications
2004
Wang LH, Wiznia AA, Rathore MH et al. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. January 2004, 48(1):183-91.
2003
Maraqa N, Alvarez AM. Infectious Arthritis. In: Klein JD, Zaoutis TE, eds. Pediatric Infectious Disease Secrets; Hanley and Belfus, Inc; 2003: 195-199.
Maraqa N, Alvarez AM. Osteomyelitis. In: Klein JD, Zaoutis TE, eds. Pediatric Infectious Disease Secrets; Hanley and Belfus, Inc; 2003: 200-207.
Starr SE, McFarland EJ, Muresau P, Fenton T, Pitt J, Douglas SD, Eveikis A, Levin MJ, Rathore MH. Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children. AIDS 2003, 17 (15): 2181-2189.
Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Spector SA, Stiehm ER, Wara DW, Douglas SD, Luzuriaga K, McFarland EJ, Yogev R, Rathore MH, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: The pediatric AIDS clinical trials group P1009 study. Journal of Allergy Clinic Immuno 2003, 112:973-80.
McComsey G, Bhumbra N, Ma J, Rathore MH, and Alvarez AM. Impact of Protease Inhibitor Substitution with Efavirenz in HIV-Infected Children: Results of the First Pediatric Switch Study. Pediatrics 2003; 111: e275-e281.
Starr SE, McFarland EJ, Muresan P, Fenton T, Pitt J, Douglas SD, Deveikis A, Levin MH, Rathore MH. Phase I/II Trial of Intravenous Recombinant Interleukin-2 in Human Immunodeficiency Virus-Infected Children. AIDS. 2003.
Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Spector SA, Stiehm ER, Wara DW, Douglas SD, Luzuriaga K, McFarland EJ, Yogev R, Rathore MH, et al. Lymphocyte subsets in Healthy Children from Birth through 18 years of Age: The Pediatric AIDS Clinical Trials Group P1009 Study. Journal of Allergy and Clinical Immunology. 2003.
McComsey G, Bhunbra N, Ma J-F, Rathore MH et al. Impact of Profease Inhibiter Substitution with Efavirenz in HIV-Infected Children: Results of the First Pediatric Switch Study. Pediatrics. 2003 III: e275-e281.